For over 30 years now, Ireland has been the home to a wealth of Lilly investment and activities. Check out our infographic below for more details of our footprint on the Emerald Isle:
We have two manufacturing sites in Ireland - in Kinsale and Sligo. We also operate a regional financial service center in Cork City and a sales and marketing office in Dublin. All told, Lilly employs roughly 700 people in Ireland.
Our facility near Kinsale in Cork is a core string to our Irish bow. The work of the dedicated, 400-strong team is essential to the development, manufacture and supply of many of the medicines in Lilly's portfolio.
In the last decade alone, Lilly has spent approximately €630 million on the campus, which now boasts a biopharmaceutical manufacturing and new-product facility (which came on-stream in 2010) as well as a state-of-the-art commercialisation and manufacturing plant.
The site was originally purchased in 1976, and production commenced in 1981. Approximately 70 percent of the total site has now been developed.
The mission of the Kinsale facility is to support the development, manufacture and supply of many of the medicines in Lilly's portfolio.
The site uses advanced chemical and biological processes to produce a range of active pharmaceutical ingredients (API) that are further processed into final drug products (pills, capsules, vials, cartridges) at other Lilly and partner facilities.
This focus continues, but the mission is expanding with the development of a centre of technical excellence, allowing the site to participate earlier in the life cycle of innovative medicines. As a result, Kinsale is now engaged in three main business activities:
Small Molecule API Manufacture & Supply The small molecule manufacturing and supply business remains core to Kinsale's mission. (A "small molecule" medicine is chemically based and typically taken orally.) We strive to be the most valued supplier of APIs for Lilly's launched medicines. Continuously improving our capabilities in small molecule manufacturing technology and ensuring operational excellence remain top priorities for the site.
Small Molecule Commercialisation More recently, Kinsale has become a centre for synthetic small molecule API commercialization (meaning Kinsale is where Lilly's newest medicines are developed and scaled up for mass production). In collaboration with Chemical Product Research and Development, Kinsale is involved in late phase product development and optimisation, which includes product technical transfers, scale-ups and clinical trial API manufacture. This also involves the implementation of new technologies such as advanced analytics, PAT and continuous processing technologies.
The site has also added to its established extensive analytical support of small molecule manufacturing with the development of new bio-analytical capabilities and is now beginning to support bioproduct analyses at other Lilly sites.
Biopharmaceutical Commercialisation and Supply In 2006, Lilly announced that Kinsale would become the main centre for the manufacture and supply of active ingredients for its new biopharmaceutical--or "large molecule"--medicines. (A "large-molecule" medicine is biologically sourced and typically is injected rather than taken orally.) To support this changing mission, a significant investment in biopharmaceutical manufacturing and commercialisation facilities was made, and operations commenced in 2011.
This investment has allowed the site to diversify into technologies to produce monoclonal antibodies (mAb's) and provides the capability to further develop newly discovered medicines in partnership with research and development colleagues in the US.